Analysis: Failed Alzheimer's Drug May Get Second Chance, Pfizer Inc. Reveals
Published: Aug 09, 2012
Pfizer and Johnson & Johnson's Alzheimer's drug failed to help patients showing early signs of the disease, but it could get another chance as scientists test whether the devastating illness should be treated before symptoms appear. Pfizer and J&J said on Monday that they were scrapping large-scale clinical trials of the experimental drug bapineuzumab in patients with mild to moderate Alzheimer's disease, after the drug failed to improve their memory or thinking skills.